Earnings results for Zymeworks (NYSE:ZYME)
Estimate Momentum measures change in analyst sentiment over time and may be an indicator of future price movements. The Change in Consensus chart shows the current, 1 week ago, and 1 month ago consensus earnings per share (EPS*) forecasts. For the fiscal quarter endingJun 2020 , the consensus EPS* forecast has remained the same over the past week at -0.86 and increased over the past month from -0.87 to -0.86(1.15%). Of the 1 analysts making quarterly forecasts, 1raised and none lowered their forecast. For the fiscal year ending Dec 2020 , the consensus EPS* forecast has remained the same over the past week at -3.37 and increased over the past month from -3.45 to -3.37(2.32%). Of the 2 analysts making yearly forecasts, 2raised and none lowered their forecast.
Zymeworks last released its earnings results on August 5th, 2020. The reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.09. Zymeworks has generated ($3.83) earnings per share over the last year. Zymeworks has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, August 7th, 2020 based off prior year’s report dates.
Analyst Opinion on Zymeworks (NYSE:ZYME)
11 Wall Street analysts have issued ratings and price targets for Zymeworks in the last 12 months. Their average twelve-month price target is $53.70, suggesting that the stock has a possible upside of 71.73%. The high price target for ZYME is $70.00 and the low price target for ZYME is $42.00. There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”
Zymeworks has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 9 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $53.70, Zymeworks has a potential upside of 71.7% from its current price of $31.27. Zymeworks has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Dividend Strength: Zymeworks (NYSE:ZYME)
Zymeworks does not currently pay a dividend. Zymeworks does not have a long track record of dividend growth.
Insiders buying/selling: Zymeworks (NYSE:ZYME)
In the past three months, Zymeworks insiders have not sold or bought any company stock. Only 4.20% of the stock of Zymeworks is held by insiders. 71.99% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Zymeworks (NYSE:ZYME
Earnings for Zymeworks are expected to decrease in the coming year, from ($3.37) to ($4.11) per share. The P/E ratio of Zymeworks is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Zymeworks is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Zymeworks has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here